Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis

Elaine C Jolly, Menna R Clatworthy, Christopher Lawrence, Paul D Nathan, Ken Farrington

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
6 Downloads (Pure)


Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities. We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (CP-675, 206), an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody. High-dose steroid therapy led to a rapid improvement in renal function, avoiding the need for renal replacement therapy.

Original languageEnglish
Pages (from-to)300-2
Number of pages3
JournalNDT Plus
Issue number4
Publication statusPublished - 28 Apr 2009


  • Journal Article


Dive into the research topics of 'Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis'. Together they form a unique fingerprint.

Cite this